PAVM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
33.0K
+50.0%
22.0K
-57.7%
52.0K
+940.0%
5.0K
-16.7%
6.0K
Cost of Revenue
122.0K
+25.8%
97.0K
+14.1%
85.0K
+54.5%
55.0K
+34.1%
41.0K
Gross Profit
-89000
-18.7%
-75000
-127.3%
-33000
+34.0%
-50000
-42.9%
-35000
Operating Expenses
3.8M
-52.5%
8.0M
+17.6%
6.8M
+41.2%
4.8M
+213.3%
1.5M
R&D
2.1M
+48.9%
1.4M
-24.1%
1.8M
+68.0%
1.1M
+37.7%
790.0K
SG&A
1.7M
-73.9%
6.6M
+33.0%
4.9M
+33.4%
3.7M
+400.8%
740.0K
Operating Income
-3872000
+51.8%
-8035000
-18.1%
-6803000
-40.4%
-4844000
-209.5%
-1565000
EBITDA
-3853000
+51.9%
-8015000
-18.1%
-6785000
-37.8%
-4925000
-219.2%
-1543000
Net Income
-6598000
-520.1%
-1064000
+61.4%
-2757000
+54.1%
-6011000
+51.2%
-12324000
EPS (Basic)
$-0.87
+80.3%
$-4.42
$-8.70
+60.6%
$-22.08
EPS (Diluted)
$-0.87
+80.3%
$-4.42
$-8.70
+60.6%
$-22.08
Shares (Diluted)
6.3M
+296.6%
1.6M
718.5K
+19.2%
602.8K
PAVmed (PAVM) — Financials